Clinical outcomes after direct and indirect surgical venous thrombectomy for inferior vena cava thrombosis.


Journal

Journal of vascular surgery. Venous and lymphatic disorders
ISSN: 2213-3348
Titre abrégé: J Vasc Surg Venous Lymphat Disord
Pays: United States
ID NLM: 101607771

Informations de publication

Date de publication:
May 2019
Historique:
received: 01 08 2018
accepted: 07 11 2018
pubmed: 12 3 2019
medline: 10 3 2020
entrez: 12 3 2019
Statut: ppublish

Résumé

Inferior vena cava thrombosis is rare, but patients are at high risk for development of a post-thrombotic syndrome (PTS) in the long term. Surgical approaches include indirect transfemoral venous thrombectomy (iTFVT) and direct open venous thrombectomy (dOVT). This study reports patient outcomes after iTFVT and dOVT for inferior vena cava thrombosis covering a 25-year follow-up period. The study period was from January 1, 1982, to December 31, 2013. Data were retrieved from archived medical records, and patients were invited for a detailed phlebologic follow-up examination (DPFE). Health-related quality of life was assessed with the 36-Item Short Form Health Survey questionnaire. Patient survival, patency rates, and freedom from PTS were calculated using Kaplan-Meier estimation with log-rank testing. The χ Complete medical records were available for 152 patients. Patients' 5-year survival was 91% ± 3%, and 5-year primary and secondary patency rates were 80% ± 3% and 94% ± 2%. Freedom from PTS after 25 years was 84% ± 6%. No differences for patient survival, patency rates, or freedom from PTS were identified between iTFVT, dOVT, and a combination of both procedures. Antithrombin III deficiency was the most common coagulation disorder, and patients' physical function and social function were impaired compared with those found in German normative data (P < .05). No risk factor or coagulation disorder was associated with survival or PTS. Open surgical venous thrombectomy is safe and delivers satisfying short- and long-term outcomes compared with endovascular approaches. It remains valuable for patients who are not eligible for other interventional therapies.

Identifiants

pubmed: 30853561
pii: S2213-333X(19)30059-9
doi: 10.1016/j.jvsv.2018.11.005
pii:
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

333-343.e2

Informations de copyright

Copyright © 2019 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Auteurs

Markus U Wagenhäuser (MU)

Department of Vascular and Endovascular Surgery, Heinrich-Heine University, Düsseldorf, Germany.

Christos Dimopoulos (C)

Department of Vascular and Endovascular Surgery, Heinrich-Heine University, Düsseldorf, Germany. Electronic address: christos.dimopoulos@med.uni-duesseldorf.de.

Kamile Antakyali (K)

Department of Vascular and Endovascular Surgery, Heinrich-Heine University, Düsseldorf, Germany.

Yvonne K Meyer-Janiszewski (YK)

Department of Vascular and Endovascular Surgery, Heinrich-Heine University, Düsseldorf, Germany.

Joscha Mulorz (J)

Department of Vascular and Endovascular Surgery, Heinrich-Heine University, Düsseldorf, Germany; Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, Calif.

Wiebke Ibing (W)

Department of Vascular and Endovascular Surgery, Heinrich-Heine University, Düsseldorf, Germany.

Neslihan Ertas (N)

Department of Vascular and Endovascular Surgery, Heinrich-Heine University, Düsseldorf, Germany.

Joshua M Spin (JM)

Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, Calif.

Hubert Schelzig (H)

Department of Vascular and Endovascular Surgery, Heinrich-Heine University, Düsseldorf, Germany.

Mansur Duran (M)

Department of Vascular and Endovascular Surgery, Heinrich-Heine University, Düsseldorf, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH